Top

Published in:

01-08-2007 | Current Status

EGFR-Targeted Therapies in Colorectal Cancer

Authors: Michael J. Overman, M.D., Paulo M. Hoff, M.D., F.A.C.P.

Published in: Diseases of the Colon & Rectum | Issue 8/2007

Abstract

The management of colorectal cancer relies heavily on the combination of the pyrimidine analog antimetabolite 5-fluorouracil with the platinum-based drug oxaliplatin or the topoisomerase inhibitor irinotecan. Optimization of dosing and scheduling of these agents to improve response and survival continues to evolve. Meanwhile, the rational targeting of molecular signaling pathways that are involved in the etiology of malignancies is currently one of the most promising strategies in novel anticancer drug development. New classes of drugs that target the epidermal growth factor receptor are among the most clinically advanced molecular-targeted therapies and have shown efficacy in colorectal cancer. The current status of epidermal growth factor receptor-targeted therapeutic agents is reviewed, with emphasis on their role in the management of colorectal cancer.

Rutman, RJ, Cantarow, A, Paschkis, KE 1954Studies in 2-acetylaminofluorene carcinogenesis. II. The in vitro uptake of alanine-1-C14 by preneoplastic liver and hepatoma mitochondrial proteinCancer Res14115118PubMed

Vogelstein, B, Kinzler, KW 2004Cancer genes and the pathways they controlNat Med10789799PubMedCrossRef

Yano, S, Kondo, K, Yamaguchi, M, et al. 2003Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibitionAnticancer Res2336393650PubMed

Venook, AP 2005Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinomaCancer10324352446PubMedCrossRef

Yarden, Y, Sliwkowski, MX 2001Untangling the ErbB signalling networkNat Rev Mol Cell Biol2127137PubMedCrossRef

Mendelsohn, J, Baselga, J 2003Status of epidermal growth factor receptor antagonists in the biology and treatment of cancerJ Clin Oncol2127872799PubMedCrossRef

McKay, JA, Murray, LJ, Curran, S, et al. 2002Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastasesEur J Cancer3822582264PubMedCrossRef

Cunningham, D, Humblet, Y, Siena, S, et al. 2004Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med351337345PubMedCrossRef

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colorectal cancer. Version 2. 2006. 11–15–2005

10.

Moroni, M, Veronese, S, Benvenuti, S, et al. 2005Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort studyLancet Oncol6279286PubMedCrossRef

11.

Lenz H-J, Mayer RJ, Mirtsching B, et al. Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:255s:3536a

12.

Saltz LB, Lenz H, Kindler H, et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:248s:3508a

13.

Grothe W, Arnold D, Peinert S, et al. Cetuximab with oxaliplatin and capecitabine (CAPOX) in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:288s:3669a

14.

Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2005;22:249s:3513a

15.

Diaz-Rubio E, Tabernero J, Van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)—expressing metastatic colorectal cancer: An international phase II study. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:254s:3535a

16.

Jennis A, Polikoff J, Mitchell E, et al. Erbitux (cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized phase III trial. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:265s:3574a

17.

Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:251s:3520a

18.

Benson A. Panitumumab, a fully-human IgG2 antibody treatment for colorectal cancer. Paper presented at: The 23rd annual Chemotherapy Foundation Symposium November 2--5, 2005, New York, New York [Abstract 4]

19.

Peeters M, Van Cutsem E, Siena S, et al. A phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs BSC alone in patients with metastatic colorectal cancer. Paper presented at: American Association of Cancer Research Annual Meeting; April 1, 2006; Washington, DC [Abstract CP-1]

20.

Vanhoefer, U, Tewes, M, Rojo, F, et al. 2004Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptorJ Clin Oncol22175184PubMedCrossRef

21.

Trarbach T, Beyer T, Schleucher N, et al. A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:199s:3018a

22.

Rothenberg, ML, LaFleur, B, Levy, DE, et al. 2005Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinomaJ Clin Oncol2392659274PubMedCrossRef

23.

Kindler, HL, Friberg, G, Skoog, L, Wade-Oliver, K, Vokes, EE 2005Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancerAm J Clin Oncol28340344PubMedCrossRef

24.

Veronese, ML, Sun, W, Giantonio, B, et al. 2005A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancerBr J Cancer9218461849PubMedCrossRef

25.

Kuo, T, Cho, CD, Halsey, J, et al. 2005Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancerJ Clin Oncol2356135619PubMedCrossRef

26.

Fisher GA, Kuo T, Cho CD, et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:248s:3514

27.

Zampino MG, Lorizzo K, Massacesi C, et al. First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:285s:3659a

28.

Jimeno A, Sevilla I, Gravalos C, et al. Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:235s:3176a

29.

Oza AM, Townsley CA, Siu LL, et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31, 2003; Chicago, Illinois [Abstract 785]

30.

Keilholz U, Arnold D, Niederle N, et al. Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer: results of a multicenter two-cohort phase II trial. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:264s:3575a

31.

Meyerhardt JA, Xhu A, Enzinger PC, et al. Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2005;22:265s:3580a

32.

Fields AL, Rinaldi DA, Henderson CA, et al. An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:266s:3583a

33.

Mendelsohn, J, Baselga, J 2000The EGF receptor family as targets for cancer therapyOncogene1965506565PubMedCrossRef

34.

Petit, AM, Rak, J, Hung, MC, et al. 1997Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumorsAm J Pathol15115231530PubMed

35.

Mellstedt, H 2003Monoclonal antibodies in human cancerDrugs of Today39116PubMed

36.

Khazaeli MB, LoBuglio AF, Falcey JW, Paulter VJ, Fetzer KM, Waksal HW. Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor recepto-positive tumors. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 20, 2000; New Orleans, Louisiana [Abstract 808]

37.

Schrag, D, Chung, KY, Flombaum, C, Saltz, L 2005Cetuximab therapy and symptomatic hypomagnesemiaJ Natl Cancer Inst9712211224PubMedCrossRef

38.

Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Paper presented at: American Society of Clinical Oncology Annual Meeting; May 12, 2001; San Francisco, California [Abstract 7]

39.

Rosenberg AH, Loehrer P, Needle MN, et al. Erbitux (IMC-C255) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EFGr). Paper presented at: American Society of Clinical Oncology Annual Meeting; May 18, 2002; Orlando, Florida [Abstract 536].

40.

Spitzer G, Zackon I, Stella P, Zehngebot L, Henderson C. Anti-epidermal growth factor (EGFR) antibody, cetuximab, in patients with stage IV colorectal carcinoma who failed all standard therapy: Final report of an access protocol. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:282s:3646a

41.

Foon, KA, Yang, XD, Weiner, LM, et al. 2004Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyInt J Radiat Oncol Biol Phys58984990PubMedCrossRef

42.

Berlin J, Malik I, Picus J, et al. Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in patients (pts) with metastatic colorectal cancer (mCRC). Ann Oncol 2004;15(Suppl 3):70

43.

Crombet, T, Osorio, M, Cruz, T, et al. 2004Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patientsJ Clin Oncol2216461654PubMedCrossRef

44.

Pfister D, Lipton A, Belt R, et al. A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody (BsAB) MDX-447 in patients with solid tumors. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 15, 1999; Atlanta, Georgia [Abstract 1667]

45.

Thatcher, N, Chang, A, Parikh, P, et al. 2005Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet36615271537PubMedCrossRef

46.

Arteaga, CL 2003ErbB-targeted therapeutic approaches in human cancerExp Cell Res284122130PubMedCrossRef

47.

Bridgewater JA, Harrison M, Broby S, Currie C, Propper D. Phase I clinical trial of Gefitinib and 5FU in patients with 5FU-refractory colorectal cancer. Paper presented at: American Society of Clinical Oncology Annual Meeting Gastrointestinal Cancers Symposium; January 27, 2005; Miami, Florida [Abstract 292]

48.

Barber, TD, Vogelstein, B, Kinzler, KW, Velculescu, VE 2004Somatic mutations of EGFR in colorectal cancers and glioblastomasN Engl J Med3512883PubMedCrossRef

49.

Delord JP, Beale P, Van Cutsem E, et al. A phase Ib dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:266s:3585a

50.

Messersmith WA, Baker SD, Dinh K, et al. Phase I trial and biologic study of Erlotinib combined with FOLFOX-4 in patients with advanced colorectal cancer: initial results. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:208s:3052a

51.

Versola M, Burris HA, Jones S, et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:206s:3047a

52.

Schwartz G, Chu SC, Hammond LA, et al. Phase I clinical, biology and pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:212s:3070a

53.

Tejpar S, Van Cutsem E, Gamelin E, et al. Phase 1/2a study of EKB-569,an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:264s:3579a

54.

Casado E, Folprecht G, Paz-Ares L, et al. A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:255s:3543a

55.

Nemunaitis JJ, Eiseman I, Cunningham C, et al. A phase 1 trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31, 2003; Chicago, Illinois

Title: EGFR-Targeted Therapies in Colorectal Cancer
Authors: Michael J. Overman, M.D.
Paulo M. Hoff, M.D., F.A.C.P.
Publication date: 01-08-2007
Publisher: Springer-Verlag
Published in: Diseases of the Colon & Rectum / Issue 8/2007
Print ISSN: 0012-3706
Electronic ISSN: 1530-0358
DOI: https://doi.org/10.1007/s10350-007-0228-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

EGFR-Targeted Therapies in Colorectal Cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2007

RAGE Activation by S100P in Colon Cancer Stimulates Growth, Migration, and Cell Signaling Pathways

Selected Abstracts

Anal Fissure

Challenges in Inflammatory Bowel Disease. Second edition.

Adjuvant Immunochemotherapy with Protein-Bound Polysaccharide K for Colon Cancer in Relation to Oncogenic β-Catenin Activation

Clinical and Pathologic Evaluation of Patients with Recurrence of Colorectal Cancer Five or More Years After Curative Resection